

SHYCOCAN®

AIR PURIFIER FOR SAFE, REAL-TIME ATTENUATION OF CORONAVIRUSES¹

Scalene Hypercharge Corona Canon (SHYCOCAN®), enables medical recirculation of purified air in indoor spaces by disabling certain coronaviruses, including the virus associated with COVID-19. The device is simple and portable, tested for efficacy against air-and surface-borne SARS-CoV-2 in National and International Biosafety Level 2 and 3 laboratories of high repute. Exposure to atmospheric and surface contamination of SARS-CoV2 that can randomly occur, can be prevented by 24/7 deployment of this innovative air purifier technology.

The negative charge-seeking guidance mechanism of the virus' Spike Protein is disabled and neutralized by the instantaneous generation of trillions of photoelectrons by the SHYCOCAN®. This high-intensity discharge of photoelectrons relies on the precision design and geometry of the proprietary Photon-Mediated Electron Emitters (PMEE) in the device. The device can be readily and cost-effectively manufactured.

Note: For detailed information, market-specific questions and FAQs, please visit www.shreis.org OR schedule a briefing (info@shreis.org).

FEATURES & BENEFITS

- ✓ **99.994% (>4Log₁₀) reduction** in a standard decontamination assay with Bacteriophage MS2
- ✓ ***99.963% reduction of an EPA-standard SARS-CoV-2 surrogate** coronavirus, in BSL-2 facilities
- ✓ **US BSL-3 lab report shows efficacy against aerosolized, live SARS-CoV-2 in real-time**
- ✓ SARS-CoV-2 surface contamination on stainless steel was **reduced by > 95% in assays reported by the TNO Institution (Netherlands)** after 15 minutes of exposure
- ✓ A premier CSIR lab (in India) reported 90% reduction of SARS-CoV-2 contamination on plastic surfaces in 10 and 30 minutes and **96% reduction in 60 minutes of exposure** respectively
- ✓ **Effective elimination of infective Influenza B viral loads**, in BSL-2 facilities
- ✓ **EU-CE Class I Designation upheld by Health Canada, and Mexican COFEPRIS in N. America**
- ✓ **Effective** against Equine, Avian and Feline coronaviruses
- ✓ Intended for over-the-counter use
- ✓ Tested and established as **non-toxic and safe**, without affecting viability of human bronchial epithelial cells
- ✓ **Spatial coverage per device up to 1000 ft² / 10,000 ft³**
- ✓ Bacteria, fungi, or other eco-friendly micro-organisms are not targeted
- ✓ **24/7 deployment** in locations occupied with people/pets/plants
- ✓ **Novel technology** without ozone emission, use of hazardous chemicals, aerosols, ultraviolet light, ionization, or plasma generation
- ✓ Intended for use in commercial, corporate, educational, faith-based, healthcare, medical, industrial, mass transit, residential settings etc.
- ✓ Instantaneous photoelectron generation on the switch of a button like when a light is turned on in a room
- ✓ **Plug and play device** with no setup required except for mounting on a wall, pedestal or table-top
- ✓ Can be **run continuously and operates on standard 110/240 volts wall outlets**. No additional consumables required
- ✓ One-year warranty for manufacturing defects



SHYCOCAN® Device with proprietary Photon-Mediated Electron Emitters (PMEEs) behind porous safety shielding²

ABOUT SHREIS

Shreis Scalene Group of LLCs - Shreis Scalene Therapeutics LLC prioritized the [SHYCOCAN®](#) device project intended to deactivate certain viruses, including coronaviruses, the virus associated with COVID-19. The Shreis Scalene Group of Therapeutic and Diagnostic medical device companies is head-quartered in Gaithersburg, MD, USA. Together with the Inventor and Technology partner, Dr. Rajah Vijay Kumar, the Shreis Scalene Group is bringing novel, non-invasive, engineering solutions for human health problems. These include the [CYTOTRON®](#) with US-FDA Breakthrough Designation granted for solid tumors of the Breast, Liver and Pancreas (among other solid tumors clinically validated in off-shore clinical studies); tissue regeneration (in musculoskeletal disorders, degenerative respiratory disorders, wound healing etc.); the [CELLFORN®](#) for safe, non-invasive cancer drug delivery; and the [HAEMOSEIS-256®](#) - a diagnostic cardiovascular disease detection device; for North and South American markets, including Mexico and the Caribbean. Shreis' mission is to introduce leading-edge platform technologies that will impact the survivorship experience with quality of life, and continue to offer global solutions for safer, patient-centric, affordable healthcare.

¹The SHYCOCAN® was market-enabled under U.S. FDA Enforcement Discretion until November 2023. Product development is currently on-going for the US-market.

²Peer-reviewed publication in progress.

